drugset / Trial / NCT00888043
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
NaSingle-groupOpen-label
Summary
The purpose of this research study is to find out what side effects the combination of the two study drugs, bevacizumab (Avastin) and CNTO 95 have on the body and to determine the highest dose of CNTO 95 that can be given with bevacizumab that is safe and well tolerated.
Timeline
- Start
- 2009-03
- Primary completion
- 2014-12
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Intetumumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Intetumumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Intetumumab | Monoclonal antibody | 10 mg/kg | Intravenous |